Phone: 732-445-3400, ext. 227
Ph.D., Albert Einstein College of Medicine, 1979
Professional Summary/CV [.PDF]
Department of Chemical Biology, Ernest Mario School of Pharmacy, New Brunswick; Department of Genetics, School of Arts and Sciences, New Brunswick; Rutgers
Areas of Interest
Molecular mechanisms of melanoma development.
Molecular Biology and Pharmaceutical Biotechnology, Pharmacogenetics, Biochemical toxicology, Molecular Toxicology.
Memberships and Professional Service
NCI (National Cancer Institute) Special Emphasis Panel, ad hoc, 2006 (July-October); NCI Oncology Fellowship, ad hoc, 2006 (March); The Board of Trustees Award for Excellence in Research, Rutgers, the State University of New Jersey, 2005; NCI Tumor Cell Biology Study Section, member, 2004-2009; NCI Cancer Genetics Study Section, ad hoc, 2004 (June); NCI Program Project Parent Subcommittee C, ad hoc, 2004 (May); USDA Grants Reviews, 2003-2005.
Grants, Honors, and Awards
New Jersey Sciences and Technology Grant, 2005-2007; Technology Commercialization Fund, 2005-2007; National Institutes of Health Grant, 2004-2009; Melanoma Research Foundation, 2004-2006; NIEHS (National Institutes of Environmental Health Science) Exploratory Research Grant, 2001-2002; The Cancer Institute of New Jersey Junior Faculty Research Award, 1995-1996; New York Obesity Research Center Award, 1994-1996; Charles and Johanna Busch Biomedical Research Award, 1993-1995.
Academic Interests and Plans
The main interest in my laboratory is to study the molecular mechanisms of melanoma development using a line of transgenic mice (TG-3) generated in my lab several years ago. From mapping studies, we have determined that about 70 kb of host sequences have been deleted by the insertion of the transgene. The host DNA had been deleted from a region of mouse chromosome 10 which is syntenic to the long arm of human chromosome 6. A combination of techniques were used to identify intron 3 of metabotropic glutamate receptor 1 (Grm1) as the gene disrupted by the insertion of the transgene. The metabotropic glutamate receptors (mGluRs) belong to a family of seven transmembrane domain, G-protein coupled receptors (GPCRs). Expression of mGluRs is usually restricted to neuronal cells, but the signaling pathways activated by these receptors are widely distributed in both neural and non-neural cells. Mice with null mutations in Grm1 display reductions in hippocampal long term potentiation, and abnormalities of motor coordination and associative learning. In the TG-3 line, we showed that Grm1 is expressed only in ear tumors, but not normal ear as demonstrated by semi-quantitative RT-PCR, Western immunoblots, immunofluorescence and immunohistochemistry. Co-localization of Grm1 and the melanocyte-marker Tyrp-1 was detected only in tumors and not in the normal counterparts. Based on these results, a new transgenic line was generated with targeted Grm1 expression to melanocytes, by using Grm1 cDNA under the melanocyte-specific Dct (dopachrome tautomerase) promoter. Founder of Dct-Grm1 exhibited melanotic tumors on the tail at 7.5 months of age. High levels of Grm1 expression were observed in tail tumors but not in normal tail. Histopathological analysis showed these tumors to be very similar to those of TG-3. These results provide the compelling evidence suggesting the improtance of Grm1 signaling in melanocytic neoplasia.
Together with Dr. J. Goydos at CINJ, we begin to explore the potential role of the aberrant expression of Grm1 in human melanoma development and progression. Our data on human melanoma biopsy samples (7/19) showed expression of Grm1. Grm1 expression was not detected in two benign nevi and one normal skin samples. Similar analyses were also done with 18 human melanoma cell lines, 12/18 of these cell lines showed Grm1 expression, these results were confirmed by immunofluorescence. Co-localization of Grm1 and Tyrp1 (a melanocyte-specific marker) was detected only in lines that also showed Grm1 expression.
How Grm1 mediates intracellular signaling in melanocytes is the main topic of our research interests.